<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In this method, most of the drug encapsulated in the polymer prior to foaming will remain in the microporous foamed product [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>,
 <xref rid="B21-pharmaceutics-11-00021" ref-type="bibr" class="xref">21</xref>]. One drawback of the two-step encapsulation and foaming process is that an organic solvent is typically used in the first step. However, as CO
 <sub class="sub">2</sub> is able to penetrate into the polymer matrix, the residual solvent is also removed by the CO
 <sub class="sub">2</sub> during the foaming process, leaving behind a product with very low residual solvent content [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>]. In our earlier studies, it was observed that the residual solvent in spray-dried particles of paclitaxel-loaded PLGA (using dichloromethane as the solvent) is reduced significantly after the CO
 <sub class="sub">2</sub> foaming process [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>]. Formulations encapsulating chitosan [
 <xref rid="B13-pharmaceutics-11-00021" ref-type="bibr" class="xref">13</xref>], paclitaxel [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>], curcumin, and gentamicin [
 <xref rid="B21-pharmaceutics-11-00021" ref-type="bibr" class="xref">21</xref>] for applications as implants or scaffolds have been demonstrated using this method. The active ingredient will be encapsulated within the matrix of the microporous structure, and drug release will follow a diffusion mechanism and/or follow the degradation of the polymer matrix [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>,
 <xref rid="B106-pharmaceutics-11-00021" ref-type="bibr" class="xref">106</xref>]. The microporous structure as a drug delivery device is particularly useful for the delivery of drugs with low bioavailability and low solubility. The high surface to volume ratio of the formulation enhances the drug release by diffusion [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>,
 <xref rid="B106-pharmaceutics-11-00021" ref-type="bibr" class="xref">106</xref>].
</p>
